MichaelS.Binkley,1,2M.ShahzadRauf,3SarahA.Milgrom,4ChelseaC.Pinnix,4RichardTsang,5MichaelDickinson,6AndreaK.Ng,7,8KennethB.Roberts,9SarahGao,9AlexBalogh,10UmbertoRicardi,11MarioLevis,11CarlaCasulo,12MichaelStolten,13LenaSpecht,14JohnP.Plastaras,15ChristopherWright,15ChristopherR.Kelsey,16JessicaL.Brady,17N.GeorgeMikhaeel,17BradfordS.Hoppe,18,19StephanieA.Terezakis,20MarcoPicardi,21RobertaDellaPepa,21YouliaKirova,22SaadAkhtar,3IrfanMaghfoor,3JulieL.Koenig,1,2ChristopherJackson,9ErinSong,16ShuchiSehgal,20RanjanaH.Advani,23YasodhaNatkunam,24LouisS.Constine,13HansT.Eich,25AndrewWirth,26RichardT.Hoppe1,21DepartmentofRadiationOncology,StanfordCancerInstitute,Stanford,CA;2RadiationOncology,StanfordUniversitySchoolofMedicine,Stanford,CA;3DepartmentofMedicalOncology,KingFaisalSpecialistHospitalandResearchCentre,Riyadh,SaudiArabia;4DepartmentofRadiationOncology,UniversityofTexasMDAndersonCancerCenter,Houston,TX;5DepartmentofRadiationOncology,PrincessMargaretCancerCenter,Toronto,ON,Canada;6DepartmentofMedicalOncology,PeterMacCallumCancerCentre,Melbourne,VIC,Australia;7DepartmentofRadiationOncology,Dana-FarberCancerInstitute,Boston,MA;8RadiationOncology,HarvardUniversitySchoolofMedicine,Boston,MA;9DepartmentofRadiationOncology,YaleUniversity,NewHaven,CT;10TomBakerCancerCenter,Calgary,AB,Canada;11DepartmentofRadiationOncology,UniversityofTurin,Torino,Italy;12DepartmentofMedicalOncologyand13DepartmentofRadiationOncology,UniversityofRochester,Rochester,NY;14DepartmentofOncology,Rigshospitalet,UniversityofCopenhagen,Copenhagen,Denmark;15DepartmentofRadiationOncology,UniversityofPennsylvania,Philadelphia,PA;16DepartmentofRadiationOncology,DukeUniversitySchoolofMedicine,Durham,NC;17DepartmentofClinicalOncology,Guy’sCancerCentre,Guy’sandStThomas’NHSHospital,London,UnitedKingdom;18DepartmentofRadiationOncology,UniversityofFlorida,Gainesville,FL;19DepartmentofRadiationOncology,MayoClinicFlorida,Jacksonville,FL;20DepartmentofRadiationOncology,TheJohnsHopkinsUniversitySchoolofMedicine,Baltimore,MD;21DepartmentofClinicalMedicineandSurgery,FedericoIIUniversity,Naples,Italy;22DepartmentofRadiationOncology,InstitutCurie,Paris,France;23DepartmentofMedicalOncologyand24DepartmentofPathology,StanfordUniversitySchoolofMedicine,Stanford,CA;25DepartmentofRadiationOncology,MunsterUniversity,Munster,Germany;26DepartmentofRadiationOncology,PeterMacCallumCancerCentre,Melbourne,VIC,Australia执行主编：魏辉中国医院（中国医学科学院血液学研究所）翻译：周可树医院血液科审校：宋永平医院血液科；医院血液科主任摘要关键点：
前期RT/CMT一线治疗I-II期NLPHL可获得很理想的PFS。
尽管如此，治疗决策仍需考虑晚期效应风险与潜在的转化风险。
摘要结节性淋巴细胞为主型霍奇金淋巴瘤（Nodularlymphocyte-predominantHodgkinlymphoma,NLPHL）是一种罕见的组织学变异，针对I-II期NLPHL的最佳治疗方案尚不明确。我们进行了一项多机构回顾性研究，研究对象为年-年诊断为I-II期NLPHL且年龄≥16岁的患者，这些患者接受了各种形式的治疗，包括放射治疗（radiotherapy,RT）、综合治疗（
